The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy

COVID-19 is known for its magical infectivity, fast transmission and high death toll based on the large number of infected people. From the perspective of the clinical manifestation, autopsy examination and pathophysiology, the essence of COVID-19 should be viewed as a sepsis induced by viral infection, and has the essential characteristics as sepsis induced by other pathogens. Therefore, in addition to etiological and supportive treatment, immunomodulatory therapy is also appropriate to severe COVID-19. Although there is still a lack of consensus on immunotherapy for sepsis so far, relatively rich experiences have been accumulated in the past decades, which will help us in the treatment of severe COVID-19. This article will elaborate immunotherapy of sepsis, though it may not be consistent.

• Tipo de recurso: Article of journal
• Fecha de publicación: 2020
• Institución: Universidad de Bogotá Jorge Tadeo Lozano
• Repositorio: Expeditio: repositorio UTadeo
• Idioma: spa
• OAI Identifier: oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/15302
• Acceso en línea: https://www.sciencedirect.com/science/article/pii/S1008127520301449?via%3Dihub; http://hdl.handle.net/20.500.12010/15302; https://doi.org/10.1016/j.cjtee.2020.06.002
• Palabra clave: Sepsis; Immunomodulatory therapy; Immunotherapy; Ulinastatin; Thymosin a1; Síndrome respiratorio agudo grave; COVID-19; SARS-CoV-2; Coronavirus
• License: Acceso restringido